AZD1775 or cisplatin alone repressed GC tumor growth to some extent, while their coadministration exerted a greater antigrowth efficiency than their single-agent groups without weight loss (Figure 4(a)), which was further validated by the lowest proliferation rate marked by Ki-67 immunostaining in GC tumors cotreated with AZD1775 and cisplatin (Figure 4(b)). Here, MKI67 is linked to neoplasm.